The invention relates to systems and methods for disinfecting, recharging, and conditioning zirconium phosphate in a reusable sorbent module. The systems and methods provide for reuse of a zirconium phosphate sorbent module after dialysis.
Zirconium phosphate containing sorbent cartridges are used in dialysis to remove ammonium, potassium, calcium, and magnesium ions from dialysate, allowing the dialysate to be reused. Known systems require zirconium phosphate to be removed from a sorbent cartridge, transported to a reprocessor, treated, and placed into a new sorbent cartridge, increasing costs and waste associated with reuse of zirconium phosphate. Known systems and methods also cannot reuse a zirconium phosphate sorbent module by concurrently disinfecting the zirconium phosphate to reduce the microbial load to acceptable levels, recovering the capacity of the zirconium phosphate, and conditioning the zirconium phosphate to an appropriate chemical state for dialysis. Hence, there is a need for systems and methods that can quickly and effectively disinfect, recharge and condition zirconium phosphate in a reusable sorbent module. There is further a need for systems and methods optimized to carry out all three steps with the least amount of waste at reduced cost than known systems and methods.
The first aspect of the invention relates to a method of recharging zirconium phosphate in a zirconium phosphate sorbent module. In any embodiment, the method can include flowing a disinfectant solution through the zirconium phosphate sorbent module; and flowing a brine solution through the zirconium phosphate sorbent module.
In any embodiment, the method can include the step of flowing water through the zirconium phosphate sorbent module after the steps of flowing disinfectant solution and brine solution through the zirconium phosphate sorbent module.
In any embodiment, the disinfectant solution can be a peracetic acid solution and the brine solution can contain acetic acid, sodium acetate, and sodium chloride.
In any embodiment, the brine solution can contain between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
In any embodiment, the disinfection solution can contain between 0.1 to 3 wt % peracetic acid.
In any embodiment, the disinfection solution can contain between 0.1 to 3 wt % peracetic acid and between 0.1 to 15 wt % acetic acid.
In any embodiment, the step of flowing the disinfectant solution and the brine solution through the zirconium phosphate sorbent module can include flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
In any embodiment, the mixture of disinfectant solution and brine solution can be maintained at room temperature while flowing the mixture through the zirconium phosphate sorbent module.
In any embodiment, the mixture of disinfectant solution and brine solution can be maintained at room temperature for a set period of time, and then heated for a set period of time.
In any embodiment, the mixture of disinfectant solution and brine solution can have between 0.1 and 3.0 wt % peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
In any embodiment, the step of flowing a disinfectant solution through the zirconium phosphate sorbent module can include flowing a concentrated disinfectant solution and water to a static mixer to generate a dilute disinfectant solution; and flowing the dilute disinfectant solution through the zirconium phosphate sorbent module.
In any embodiment, the step of flowing a brine solution through the zirconium phosphate sorbent module can include flowing a concentrated brine solution and water to a static mixer to generate a dilute brine solution; and flowing the dilute brine solution through the zirconium phosphate sorbent module.
In any embodiment, the brine solution can be flowed through the zirconium phosphate sorbent module after the peracetic acid is flowed through the zirconium phosphate sorbent module.
In any embodiment, the peracetic acid solution can be flowed through the zirconium phosphate sorbent module after the brine solution is flowed through the zirconium phosphate sorbent module.
In any embodiment, the method can include the step of heating the brine solution prior to flowing the brine solution through the zirconium phosphate sorbent module.
In any embodiment, the brine solution can be heated to a temperature up to 100° C.
In any embodiment, the method can include flowing the brine solution to a static mixer and flowing the disinfectant solution to the static mixer prior to flowing the mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
In any embodiment, the step of flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module can include flowing the mixture from a combined disinfectant solution and brine solution source.
In any embodiment, the method can include rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module.
In any embodiment, the step of rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module can include flowing between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L of water through the zirconium phosphate sorbent module.
In any embodiment, the method can include holding the disinfectant solution in the zirconium phosphate sorbent module.
In any embodiment, the disinfectant solution can be held in the zirconium phosphate sorbent module for between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes.
In any embodiment, the method can include flowing disinfectant solution through the zirconium phosphate sorbent module at a flow rate of between 0 and 20 mL/min while holding the disinfectant solution in the zirconium phosphate sorbent module.
In any embodiment, the method can include intermittently flowing fluid through the zirconium phosphate sorbent module while holding the disinfectant solution in the zirconium phosphate sorbent module.
In any embodiment, the method can include rinsing the zirconium phosphate sorbent module with water after flowing the disinfectant solution through the zirconium phosphate sorbent module and prior to flowing the brine solution through the zirconium phosphate sorbent module.
In any embodiment, the brine solution, the water, and the disinfectant solution can be flowed through the zirconium phosphate sorbent module in a direction opposite to a flow direction during therapy.
The features disclosed as being part of the first aspect of the invention can be in the first aspect of the invention, either alone or in combination.
The second aspect of the invention is drawn to a zirconium phosphate recharging flow path. In any embodiment, the zirconium phosphate recharging flow path can include (i) a water source and a combined disinfectant solution and brine solution source; (ii) a zirconium phosphate sorbent module inlet and a zirconium phosphate sorbent module outlet; wherein the zirconium phosphate sorbent module inlet and the zirconium phosphate sorbent module outlet are fluidly connectable to a zirconium phosphate sorbent module; (iii) at least one pump for flowing fluid from the water source and the combined disinfectant solution and brine solution source to the zirconium phosphate sorbent module inlet; and; (iv) a zirconium phosphate effluent line fluidly connectable to the zirconium phosphate sorbent module outlet.
In any embodiment, the combined disinfectant solution and brine solution source can contain between 0.1 and 3.0 wt % peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
In any embodiment, the zirconium phosphate recharging flow path can include a second pump.
In any embodiment, the zirconium phosphate recharging flow path can include a static mixer, the static mixer fluidly connected to the water source and the combined disinfectant solution and brine solution source.
The features disclosed as being part of the second aspect of the invention can be in the second aspect of the invention, either alone or in combination.
Unless defined otherwise, all technical and scientific terms used generally have the same meaning as commonly understood by one of ordinary skill in the art.
The articles “a” and “an” are used to refer to one or to over one (i.e., to at least one) of the grammatical object of the article. For example, “an element” means one element or over one element.
The term “acetic acid” refers to CH3CO2H in an aqueous solution.
A “brine solution” is a solution containing sodium chloride, an acid, and the sodium salt of the acid.
The term “combined disinfectant solution and brine solution source” refers to any source of a fluid containing both a disinfectant and a brine solution.
The term “comprising” includes, but is not limited to, whatever follows the word “comprising.” Use of the term indicates the listed elements are required or mandatory but that other elements are optional and may be present.
A “concentrated” solution refers to a solution having at least one solute in a higher concentration than intended for use.
The term “consisting of” includes and is limited to whatever follows the phrase “consisting of.” The phrase indicates the limited elements are required or mandatory and that no other elements may be present.
The term “consisting essentially of” includes whatever follows the term “consisting essentially of” and additional elements, structures, acts or features that do not affect the basic operation of the apparatus, structure or method described.
A “dilute” solution refers to a concentrated solution after addition of a solvent to lower the solute concentration.
The term “direction opposite to a flow direction during therapy” refers to a direction of fluid flow through a component that is in reserver to an initial flow direction, or 180° to the initial direction of fluid flow, through the component during dialysis therapy.
The term “disinfectant solution” refers to any solution capable of destroying or removing bacterial contaminants from a reusable sorbent module.
The terms “flowing” or to “flow” refer to the movement of a fluid, gas, or mixtures thereof.
The term “flow rate” refers to a volume of fluid moved in a flow path in a given period of time.
A “fluid” is a liquid substance optionally having a combination of gas and liquid phases in the fluid. Notably, a liquid, as used herein, can therefore also have a mixture of gas and liquid phases of matter.
The term “fluidly connectable,” “fluidly connect,” “for fluid connection,” and the like, refer to the ability of providing for the passage of fluid, gas, or a combination thereof, from one point to another point. The two points can be within or between any one or more of compartments, modules, systems, components, and rechargers, all of any type. The connection can optionally be disconnected and then reconnected.
The term “generate” refers to creating a fluid with a specified concentration, pH, temperature, and/or volume from one or more fluid sources.
The term “heating” or to “heat” refers to raising the temperature of a material.
The term “holding a disinfectant solution” or to “hold a disinfectant solution” refers to adding a disinfectant solution to a component without immediate removal of the disinfectant solution. The term “holding a disinfectant solution” can also refer to flowing a disinfectant solution through the component at a low flow rate or an intermittent flow rate.
The term “intermittently” refers to a process that starts and stops multiple times.
The term “maintained at room temperature” or to “maintain at room temperature” refers to keeping a substance from increasing or decreasing in temperature substantially from room temperature.
The term “mixture” refers to a fluid having at least two components, the two components combined to form a substantially homogeneous substance.
The term “peracetic acid” refers to CH3CO3H in an aqueous solution.
The term “peracetic acid solution” refers to a solution of peracetic acid, acetic acid and hydrogen peroxide
The term “pump” refers to any device that causes the movement of fluids, gases, or combinations thereof, by applying suction or pressure.
“Recharging” refers to treating a sorbent material to restore the functional capacity of the sorbent material to put the sorbent material back into a condition for reuse or use in a new dialysis session. In some instances, the total mass, weight and/or amount of “rechargeable” sorbent materials remain the same. In some instances, the total mass, weight and/or amount of “rechargeable” sorbent materials change. Without being limited to any one theory of invention, the recharging process may involve exchanging ions bound to the sorbent material with different ions, which in some instances may increase or decrease the total mass of the system. However, the total amount of the sorbent material will in some instances be unchanged by the recharging process. Upon a sorbent material undergoing “recharging,” the sorbent material can then be said to be “recharged.”
The term “rinsing” or to “rinse” refers to flowing water through a component to remove substances from the component.
The term “room temperature” refers to the ambient temperature in an environment without additional heating or cooling. In general, room temperature can be considered between 15 and 30° C.
The term “set period of time” refers to a specific amount of time elapsed between two events.
The term “sodium acetate” refers to CH3CO2Na in an aqueous solution.
The term “sodium chloride” refers to NaCl.
A “sorbent cartridge module” or “sorbent module” means a discreet component of a sorbent cartridge. Multiple sorbent cartridge modules can be fitted together to form a sorbent cartridge of two, three, or more sorbent cartridge modules. In some embodiments, a single sorbent cartridge module can contain all of the necessary materials for dialysis. In such cases, the sorbent cartridge module can be a “sorbent cartridge.”
A “static mixer” is a component configured to receive fluids from one or multiple sources and to mix the fluids together. The static mixer may include components that agitate the fluids to further mixing.
The term “void volume” refers to a volume contained in a cartridge, not including a sorbent or any other material, through which liquid can flow. The term “void volume” can also refer to the volume of a cartridge or container available for a liquid or gas to fill the cartridge or container.
The term “water,” as used herein, refers to H2O in a liquid state. “Water” can refer to portable water, drinking water, purified water, deionized water, tap water, or a solution containing one or more solutes dissolved in the water. The water shall not be limited to any specific purity, disinfection time, toxicity, microbial load, or any other indicator of water quality.
A “water source” is a fluid source from which water can be obtained.
“Zirconium phosphate” is a sorbent material that removes cations from a fluid, exchanging the removed cations for different cations.
A “zirconium phosphate effluent line” is a fluid passageway, tube, or path of any kind into which fluid exiting a zirconium phosphate sorbent module will flow.
A “zirconium phosphate module” or “zirconium phosphate sorbent module” is a sorbent module containing zirconium phosphate.
A “zirconium phosphate sorbent module inlet” is a connector through which a fluid, slurry, or aqueous solution can enter a zirconium phosphate sorbent module.
A “zirconium phosphate sorbent module outlet” is a connector through which a fluid, slurry, or aqueous solution can exit a zirconium phosphate sorbent module.
A “zirconium phosphate recharging flow path” is a path through which fluid can travel while recharging zirconium phosphate in a reusable zirconium phosphate sorbent module.
Zirconium Phosphate Recharging, Disinfection, and Conditioning
The method of disinfecting the zirconium phosphate in a zirconium phosphate sorbent module can begin in step 101. During use in dialysis potassium, calcium, magnesium, and ammonium ions are adsorbed by the zirconium phosphate. In step 102, the zirconium phosphate sorbent module can be rinsed with water by flowing water through the zirconium phosphate sorbent module to remove any spent dialysate left in the module after therapy. The spent dialysate can have proteinaceous and other compounds that interact with the disinfectant used in subsequent steps. Rinsing the zirconium phosphate sorbent module with water removes the proteinaceous compounds. Any volume of water sufficient to remove the spent dialysate can be flowed through the zirconium phosphate sorbent module in step 102, including between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L. In a preferred embodiment, about 1.0 L of water is flowed through the zirconium phosphate sorbent module in rinsing step 102. The rinse water can be flowed through the zirconium phosphate sorbent module at any temperature. In certain embodiments, the rinse water can be heated to aid in removal of spent dialysate or for pre-heating the zirconium phosphate sorbent module. Pre-heating the zirconium phosphate sorbent module can increase efficiency where the zirconium phosphate sorbent module may have been stored at low temperatures, such as 10° C. or less. The rinse water can be heated to any temperature between 20 and 100° C.
After rinsing the zirconium phosphate sorbent module, the zirconium phosphate sorbent module can be filled with a disinfectant solution in step 103. An aqueous peracetic acid solution can be the disinfectant solution. The peracetic acid solution can have any concentration of peracetic acid sufficient to disinfect the zirconium phosphate sorbent module, including between 0.1 and 5 wt %. In a preferred embodiment, the peracetic acid solution is 1 wt % in water. The volume of peracetic acid flowed into the zirconium phosphate sorbent module can be enough to fill the zirconium phosphate sorbent module, and can be between 100% to 200% or more of the void volume of the zirconium phosphate sorbent module. In a preferred embodiment, a volume of peracetic acid solution flowed into the zirconium phosphate sorbent module is 150% of the module void volume. With a 1.2 L zirconium phosphate sorbent module, 1.8 L of peracetic acid solution can be flowed into the module in step 103.
The peracetic acid solutions can be mixtures of peracetic acid, acetic acid and hydrogen peroxide. Typically, peracetic acid is the result of mixing acetic acid and hydrogen peroxide together, resulting in the generation of peracetic acid in equilibrium with the acetic acid and hydrogen peroxide. There are several varieties of peracetic acid solution available, which vary in the concentration of peracetic acid, acetic acid, and hydrogen peroxide. In addition to peracetic acid, the disinfectant solution can be a combined peracetic acid and acetic acid solution, which increases the effectiveness of the disinfection as compared to peracetic acid alone. The combined disinfectant and acid solution can contain between 0.1 and 3 wt % peracetic acid and 0.1 to 15 wt % acetic acid. Alternatively, hydrogen peroxide can be added to the peracetic acid, which increases the effectiveness of the disinfection as compared to peracetic acid alone. The addition of hydrogen peroxide can drive the equilibrium of peracetic acid, hydrogen peroxide, and acetic acid towards generation of peracetic acid as the initial peracetic acid is consumed. Further, both peracetic acid and hydrogen peroxide can be used as disinfectants alone. Both peracetic acid and hydrogen peroxide operate by oxidation, with each having an oxidation potential of 1.8 electron volts. Adding hydrogen peroxide to the peracetic acid solution can increase the total oxidation potential of the mixture, resulting in a more potent disinfectant. Chemical formulations including mixtures of peracetic acid and hydrogen peroxide are known. The mixtures can be clear, colorless liquids that are miscible with water. The mixtures can be oxidizing agents and disinfectants with a pungent odor, having peracetic acid, acetic acid, and hydrogen peroxide in equilibrium. Thermal decomposition of the mixtures occurs at temperatures above 60° C. Known compositions of peracetic acid and hydrogen peroxide solutions are available from Evonik, a German corporation. Examples of peracetic acid and hydrogen peroxide solutions include PERACLEAN® 5 having 5% peracetic acid and 26% hydrogen peroxide, PERACLEAN® 10 having 10% peracetic acid and 20% hydrogen peroxide, PERACLEAN® 15 having 15% peracetic acid and 21% hydrogen peroxide, PERACLEAN® 35 having 35% peracetic acid and 7% hydrogen peroxide, and PERACLEAN® 40 having 39% peracetic acid and 4% hydrogen peroxide. As the concentration of peracetic acid in the mixture is decreased, additional hydrogen peroxide can be added to increase effectiveness of the mixture. The formulations, or any other source of peracetic acid and hydrogen peroxide can be diluted to obtain a solution with desired concentrations of peracetic acid and hydrogen peroxide.
In step 104, the disinfectant solution can be held in the zirconium phosphate sorbent module for a sufficient length of time to ensure complete disinfection of the zirconium phosphate sorbent module. The hold time can be any length of time, including between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes. The length of the hold time can depend on the temperature of the zirconium phosphate sorbent module, and in a preferred embodiment the hold time can be 15 minutes at 22° C. Alternatively, the disinfectant solution can be heated in steps 103-104 to a temperature higher than 22° C., which increases the efficiency of disinfection. The disinfectant can be heated to any temperature, including between 22° C. and 100° C., between 22° C. and 50° C., between 22° C. and 35C, between 30° C. and 50° C., between 35° C. and 65° C., between 50° C. and 75° C., or between 60° C. and 100° C. During step 104, a low flow rate of fluid through the zirconium phosphate sorbent module can be used to prevent pressure build up in the cartridge resulting from the degradation of peracetic acid. The low flow rate can vary from 1 to 20 ml/min. the low flow rate can have an on/off flow profile by intermittently switching the flow rate on and off while holding the disinfectant solution. The flow rate during the disinfectant hold can be set as 55 ml/min for 15 seconds and 0 ml/min for 45 seconds. In a preferred embodiment, the hold flow rate is 15 cycles of 55 ml/min for 15 seconds and 0-ml/min for 45 seconds.
In step 105, the zirconium phosphate module can be rinsed with water, allowing a buffer of water to be present between the peracetic acid solution and the subsequent brine solution. Step 105 is optional, and the method can proceed without rinsing between the peracetic acid step 104 and the brine step 106. When rinsing with water between steps 104 and 106, the volume of water used can vary between 0 and 1.0 L or more. In a preferred embodiment, step 105 is omitted. However, the zirconium phosphate module can be rinsed if material degradation to the cartridge housing or other components is detected. Material degradation may be an issue if the disinfectant used is a heated mixture of peracetic acid and acetic acid, or a mixture of peracetic acid and brine at temperatures around 80° C.
In step 106 a brine solution can be flowed through the zirconium phosphate sorbent module to recharge the zirconium phosphate. The brine solution can include an aqueous solution of sodium chloride, and acid, and the sodium salt of the acid. The brine solution provides additional disinfection of the zirconium phosphate; recovers the capacity of the zirconium phosphate by removing ammonium, potassium, calcium, and magnesium ions in exchange for sodium and hydrogen ions; and leaves the zirconium phosphate at the desired pH, or in the proper/desired sodium to hydrogen ion ratio for dialysis. Although
Any acid, sodium salt of an acid, and sodium salt can be used in the brine solution. In a preferred embodiment, the brine solution includes sodium chloride, acetic acid, and sodium acetate. However, the brine solution can be a glycolic/glycolate solution, a citric acid/citrate solution, a propionate/propionic acid solution, monobasic phosphate, or any combination thereof. The relative ratios of the acid and sodium salt of the acid in the brine solution can be varied depending on the desired zirconium phosphate pH. With a sodium acetate/acetic acid brine solution, the concentration of sodium chloride can vary between 0 and 5.0 M, the concentration of acetic acid can vary between 0.1 and 2.0 M, and the concentration of sodium acetate can vary between 0.1 and 2 M, where the upper concentration limits are only limited by solubility. The sodium chloride can be omitted in certain embodiments, and the zirconium phosphate sorbent module can be recharged with an acid and the sodium salt of the acid. The sodium salt of the acid can provide sodium ions and the acid can provide the hydrogen ions for recharging. The upper limit of the sodium salt and acid concentration is based on the solubility of the sodium salt and acid, and can depend on the type of sodium salt used and the acid concentration used. In a preferred embodiment, the brine solution contains about 4.854 M sodium chloride, 0.350 M sodium acetate, and 0.350 M acetic acid. Table 1 provides non-limiting examples of brine solutions and the resulting initial therapy zirconium phosphate effluent pH. In each case, the solution was heated to 80° C. prior to use. As shown in Table 1, a higher ratio of sodium acetate to acetic acid results in a higher solution pH, and therefore a higher initial therapy zirconium phosphate effluent pH. The relative amounts of acid, base, and sodium salt can be set to generate a brine solution resulting in a desired initial effluent pH.
Each of the solutions in Table 1 are combinations of sodium chloride, sodium acetate, and acetic acid. One of skill in the art will understand that other combinations can be used in place of sodium acetate and acetic acid, including sodium diacetate. The sodium diacetate can be mixed with sodium acetate or acetic acid to result in a brine solution having a desired pH. Sodium diacetate and sodium acetate are solids, which may be easier to ship and store. The sodium diacetate and/or sodium acetate can be shipped and stored as a dry powder, eliminating the need to ship and handle acetic acid.
During step 106, the brine solution can optionally be heated. Heating the brine solution increases the efficiency of the recharging process. The brine solution can be heated to any temperature between 22 and 100° C., including between 22 and 40° C., between 22 and 60° C., between 35 and 50° C., between 45 and 70° C., between 55 and 85° C., between 60 and 90° C., between 75 and 85° C., or between 70 and 100° C. In a preferred embodiment, the brine solution is heated to about 80° C. during step 106. The brine solution can be used at lower temperatures with a decrease in efficiency.
The volume of brine solution to recharge the zirconium phosphate depends on the cations bound to the zirconium phosphate during therapy, and the size of the zirconium phosphate sorbent module, the temperature of the brine solution, and the concentrations of sodium chloride, acid, and sodium salt of the acid used in the brine solution. In a preferred embodiment, the volume of brine is 6.2 L for a zirconium phosphate sorbent module containing 2.69 kg of ZP with a capacity of 1 mEq cation per gram of ZP.
After flowing the brine solution through the zirconium phosphate sorbent module, the zirconium phosphate sorbent module can be rinsed in step 107 by flowing water through the zirconium phosphate sorbent module. The rinsing is necessary to remove the brine solution in the zirconium phosphate sorbent module to appropriate levels for storage and use during the next therapy session. The rinse water volume can vary from 100% to 500% of the cartridge void volume. In a preferred embodiment, the volume of rinse water is about 333% of the cartridge void volume, or 4 L for a zirconium phosphate sorbent module with a 1.2 L void volume. About 99% of the brine solution can be removed from the zirconium phosphate sorbent module during step 107, which leaves the zirconium phosphate sorbent module with an average concentration remaining of 52 mM total sodium, which is appropriate for storage and use during the next therapy session. The rinsing step 107 can occur during recharging of the zirconium phosphate sorbent module, or the zirconium phosphate sorbent module can be rinsed in the dialysis system just prior to use. Rinsing the zirconium phosphate sorbent module just prior to use allows the disinfectant solution, if the disinfectant step is performed after the brine step, to remain in the zirconium phosphate sorbent module during storage, reducing microbial growth. The method can end in step 108, with a zirconium phosphate sorbent module in condition for reuse in dialysis. Alternatively, the zirconium phosphate module can be fully or partially drained after recharging and conditioning for storage, which decreases the weight and exposure to water during storage.
The direction of flow of brine through the zirconium phosphate sorbent module during step 106 can be in a direction opposite to a flow direction during therapy. During therapy, spent dialysate enters the bottom of the module, flows upwards against gravity, and exits the top of the cartridge. During recharging the brine can enter the zirconium phosphate sorbent module at the top and exit through the bottom, flowing with gravity. Alternatively, the spent dialysate flow direction during therapy can be downward, and the brine can flow upwardly through the zirconium phosphate sorbent module during recharging. The rinse and disinfection flow direction during steps 102-105 and 107 can be either the same or opposite to the flow direction during therapy. Alternatively, the direction of flow of brine during recharging can be the same as the flow direction during therapy, however, flowing brine through the zirconium phosphate module in the same direction as flow during therapy may require additional brine volume for recharging. In a preferred embodiment, the rinse and disinfection flow direction is the same direction as the brine flow direction.
The zirconium phosphate recharging flow path 301 can flow solutions through the zirconium phosphate sorbent module 302 in a sequential order or simultaneously. As illustrated in
The solutions in the brine source 305 and disinfectant source 306 can be any concentration, including the concentrations shown in
One skilled in the art will understand that various combinations and/or modifications and variations can be made in the described systems and methods depending upon the specific needs for operation. Moreover features illustrated or described as being part of an aspect of the invention may be used in the aspect of the invention, either alone or in combination.
This application claims the benefit of and priority to U.S. patent application Ser. No. 15/958,337 filed Apr. 20, 2018, which claims priority to Provisional Patent Application No. 62/519,933 filed Jun. 15, 2017, the entire disclosure of each of which is incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
1617288 | Kenney | Feb 1927 | A |
2703313 | Gill | Jan 1950 | A |
3608729 | Haselden | Sep 1971 | A |
3617545 | Dubois | Nov 1971 | A |
3617558 | Jones | Nov 1971 | A |
3669878 | Marantz | Jun 1972 | A |
3669880 | Marantz | Jun 1972 | A |
3776819 | Williams | Dec 1973 | A |
3840835 | Kussy | Oct 1974 | A |
3850835 | Marantz | Nov 1974 | A |
3884808 | Scott | May 1975 | A |
3902490 | Jacobsen | Sep 1975 | A |
3989622 | Marantz | Nov 1976 | A |
4060485 | Eaton | Nov 1977 | A |
4073725 | Takeuchi | Feb 1978 | A |
4094775 | Mueller | Jun 1978 | A |
4142845 | Lepp | Mar 1979 | A |
4192748 | Hyden | Mar 1980 | A |
4206054 | Moore | Jun 1980 | A |
4209392 | Wallace | Jun 1980 | A |
4269708 | Bonomini | May 1981 | A |
4371385 | Johnson | Feb 1983 | A |
4374382 | Markowitz | Feb 1983 | A |
4376707 | Lehmann | Mar 1983 | A |
4381999 | Boucher | May 1983 | A |
4460555 | Thompson | Jul 1984 | A |
4556063 | Thompson | Dec 1985 | A |
4562751 | Nason | Jan 1986 | A |
4581141 | Ash | Apr 1986 | A |
4612122 | Ambrus | Sep 1986 | A |
4650587 | Polak | Mar 1987 | A |
4661246 | Ash | Apr 1987 | A |
4678408 | Mason | Jul 1987 | A |
4684460 | Issautier | Aug 1987 | A |
4685903 | Cable | Aug 1987 | A |
4687582 | Dixon | Aug 1987 | A |
4750494 | King | Jun 1988 | A |
4765907 | Scott | Aug 1988 | A |
4826663 | Alberti | May 1989 | A |
4828693 | Lindsay | May 1989 | A |
5032615 | Ward et al. | Jul 1991 | A |
5047014 | Mosebach et al. | Sep 1991 | A |
5080653 | Voss | Jan 1992 | A |
5092886 | Dobos-Hardy | Mar 1992 | A |
5097122 | Coiman | Mar 1992 | A |
5127404 | Wyborny | Jul 1992 | A |
5192132 | Pelensky | Mar 1993 | A |
5230702 | Lindsay | Jul 1993 | A |
5284470 | Beltz | Feb 1994 | A |
5302288 | Meidl | Apr 1994 | A |
5305745 | Zacouto | Apr 1994 | A |
5308315 | Khuri | May 1994 | A |
5318750 | Lascombes | Jun 1994 | A |
5399157 | Goux | Mar 1995 | A |
5441049 | Masano | Aug 1995 | A |
5442969 | Troutner | Aug 1995 | A |
5445610 | Evert | Aug 1995 | A |
5468388 | Goddard | Nov 1995 | A |
5507723 | Keshaviah | Apr 1996 | A |
5662806 | Keshaviah et al. | Sep 1997 | A |
5683432 | Goedeke | Nov 1997 | A |
5685988 | Malchesky | Nov 1997 | A |
5716400 | Davidson | Feb 1998 | A |
5744031 | Bene | Apr 1998 | A |
5762782 | Kenley | Jun 1998 | A |
5770086 | Indriksons | Jun 1998 | A |
5849179 | Emerson | Dec 1998 | A |
5858186 | Glass | Jan 1999 | A |
5938634 | Packard | Aug 1999 | A |
5938938 | Bosetto | Aug 1999 | A |
5944684 | Roberts | Aug 1999 | A |
6036858 | Carlsson | Mar 2000 | A |
6048732 | Anslyn | Apr 2000 | A |
6052622 | Holmstrom | Apr 2000 | A |
6058331 | King | May 2000 | A |
6114176 | Edgson et al. | Sep 2000 | A |
6126831 | Goldau | Oct 2000 | A |
6171480 | Lee | Jan 2001 | B1 |
6176003 | Aoyama | Jan 2001 | B1 |
6230059 | Duffin | May 2001 | B1 |
6248093 | Moberg | Jun 2001 | B1 |
6254567 | Treu | Jul 2001 | B1 |
6321101 | Holmstrom | Nov 2001 | B1 |
6362591 | Moberg | Mar 2002 | B1 |
6363279 | Ben-Haim et al. | Mar 2002 | B1 |
6390969 | Bolling et al. | May 2002 | B1 |
6491993 | Forbes | Dec 2002 | B1 |
6521184 | Edgson et al. | Feb 2003 | B1 |
6554798 | Mann | Apr 2003 | B1 |
6555986 | Moberg | Apr 2003 | B2 |
6565525 | Burbank et al. | May 2003 | B1 |
6572769 | Rajan | Jun 2003 | B2 |
6579460 | Willis | Jun 2003 | B1 |
6585675 | O'Mahony et al. | Jul 2003 | B1 |
6589229 | Connelly | Jul 2003 | B1 |
6593747 | Puskas | Jul 2003 | B2 |
6596234 | Schnell et al. | Jul 2003 | B1 |
6602399 | Fromherz | Aug 2003 | B1 |
6627164 | Wong | Sep 2003 | B1 |
6666840 | Falkvall et al. | Dec 2003 | B1 |
6676608 | Keren | Jan 2004 | B1 |
6695807 | Bell et al. | Feb 2004 | B2 |
6711439 | Bradley | Mar 2004 | B1 |
6719745 | Taylor | Apr 2004 | B1 |
6773412 | O'Mahony et al. | Aug 2004 | B2 |
6814724 | Taylor | Nov 2004 | B2 |
6818196 | Wong | Nov 2004 | B2 |
6861266 | Sternby | Mar 2005 | B1 |
6878258 | Hughes | Apr 2005 | B2 |
6878283 | Thompson | Apr 2005 | B2 |
6878285 | Hughes | Apr 2005 | B2 |
6890315 | Levin | May 2005 | B1 |
6923782 | O'Mahony et al. | Aug 2005 | B2 |
6960179 | Gura | Nov 2005 | B2 |
7029456 | Ware et al. | Apr 2006 | B2 |
7033498 | Wong | Apr 2006 | B2 |
7077819 | Goldau | Jul 2006 | B1 |
7097630 | Gotch | Aug 2006 | B2 |
7101519 | Wong | Sep 2006 | B2 |
7128750 | Stergiopulos | Oct 2006 | B1 |
7153693 | Tajiri | Dec 2006 | B2 |
7208092 | Micheli | Apr 2007 | B2 |
7241272 | Karoor | Jul 2007 | B2 |
7276042 | Polaschegg | Oct 2007 | B2 |
7309323 | Gura | Dec 2007 | B2 |
7318892 | Connell | Jan 2008 | B2 |
7326576 | Womble et al. | Feb 2008 | B2 |
7384543 | Jonsson et al. | Jun 2008 | B2 |
7435342 | Tsukamoto | Oct 2008 | B2 |
7462161 | O'Mahony et al. | Dec 2008 | B2 |
7488447 | Sternby | Feb 2009 | B2 |
7537688 | Tarumi | May 2009 | B2 |
7544300 | Brugger | Jun 2009 | B2 |
7544737 | Poss | Jun 2009 | B2 |
7563240 | Gross | Jul 2009 | B2 |
7566432 | Wong | Jul 2009 | B2 |
7575564 | Childers | Aug 2009 | B2 |
7597806 | Uchi | Oct 2009 | B2 |
7674231 | McCombie | Mar 2010 | B2 |
7674237 | O'Mahony et al. | Mar 2010 | B2 |
7686778 | Burbank et al. | Mar 2010 | B2 |
7704361 | Garde | Apr 2010 | B2 |
7736507 | Wong | Jun 2010 | B2 |
7754852 | Burnett | Jul 2010 | B2 |
7756572 | Fard | Jul 2010 | B1 |
7776001 | Brugger et al. | Aug 2010 | B2 |
7776006 | Childers | Aug 2010 | B2 |
7776210 | Rosenbaum | Aug 2010 | B2 |
7794141 | Perry | Sep 2010 | B2 |
7794419 | Paolini | Sep 2010 | B2 |
7850635 | Polaschegg | Dec 2010 | B2 |
7867214 | Childers | Jan 2011 | B2 |
7901376 | Steck et al. | Mar 2011 | B2 |
7905853 | Chapman et al. | Mar 2011 | B2 |
7922686 | Childers | Apr 2011 | B2 |
7922911 | Micheli | Apr 2011 | B2 |
7947179 | Rosenbaum | May 2011 | B2 |
7955289 | O'Mahony et al. | Jun 2011 | B2 |
7955290 | Karoor | Jun 2011 | B2 |
7967022 | Grant | Jun 2011 | B2 |
7981082 | Wang | Jul 2011 | B2 |
7988854 | Tsukamoto | Aug 2011 | B2 |
8002726 | Karoor | Aug 2011 | B2 |
8012118 | Curtin | Sep 2011 | B2 |
8029454 | Kelly | Oct 2011 | B2 |
8034161 | Gura | Oct 2011 | B2 |
8066658 | Karoor | Nov 2011 | B2 |
8070709 | Childers | Dec 2011 | B2 |
8080161 | Ding et al. | Dec 2011 | B2 |
8087303 | Beavis | Jan 2012 | B2 |
8096969 | Roberts | Jan 2012 | B2 |
8180574 | Lo | May 2012 | B2 |
8182673 | Childers et al. | May 2012 | B2 |
8183046 | Lu | May 2012 | B2 |
8187250 | Roberts | May 2012 | B2 |
8197439 | Wang | Jun 2012 | B2 |
8206591 | Kotanko et al. | Jun 2012 | B2 |
8211048 | Szamosfalvi et al. | Jul 2012 | B2 |
8221529 | Childers et al. | Jul 2012 | B2 |
8226595 | Childers et al. | Jul 2012 | B2 |
8246826 | Wilt | Aug 2012 | B2 |
8267881 | O'Mahony et al. | Sep 2012 | B2 |
8273049 | Demers | Sep 2012 | B2 |
8292594 | Tracey | Oct 2012 | B2 |
8303532 | Hamada | Nov 2012 | B2 |
8313642 | Yu | Nov 2012 | B2 |
8317492 | Demers | Nov 2012 | B2 |
8357113 | Childers | Jan 2013 | B2 |
8357298 | Demers et al. | Jan 2013 | B2 |
8366316 | Kamen | Feb 2013 | B2 |
8366655 | Kamen | Feb 2013 | B2 |
8376999 | Busby et al. | Feb 2013 | B2 |
8377012 | Chapman et al. | Feb 2013 | B2 |
8377308 | Kreymann et al. | Feb 2013 | B2 |
8388567 | Rovatti | Mar 2013 | B2 |
8404491 | Li | Mar 2013 | B2 |
8409441 | Wilt | Apr 2013 | B2 |
8409444 | Wong | Apr 2013 | B2 |
8449487 | Wallenborg et al. | May 2013 | B2 |
8480607 | Davies | Jul 2013 | B2 |
8499780 | Wilt | Aug 2013 | B2 |
8518260 | Raimann | Aug 2013 | B2 |
8535525 | Heyes | Sep 2013 | B2 |
8580112 | Updyke | Nov 2013 | B2 |
8597227 | Childers | Dec 2013 | B2 |
8647506 | Wong | Feb 2014 | B2 |
8696626 | Kirsch | Apr 2014 | B2 |
8733559 | Wong | May 2014 | B2 |
8764981 | Ding | Jul 2014 | B2 |
8777892 | Sandford | Jul 2014 | B2 |
8903492 | Soykan | Dec 2014 | B2 |
9144640 | Pudil | Sep 2015 | B2 |
9254355 | Sandford | Feb 2016 | B2 |
9527015 | Chau | Dec 2016 | B2 |
20010007931 | Blatter | Jul 2001 | A1 |
20010009756 | Hei et al. | Jul 2001 | A1 |
20020016550 | Sweeney | Feb 2002 | A1 |
20020027106 | Smith | Mar 2002 | A1 |
20020042561 | Schulman | Apr 2002 | A1 |
20020062098 | Cavicchioli et al. | May 2002 | A1 |
20020112609 | Wong | Aug 2002 | A1 |
20020117436 | Rajan | Aug 2002 | A1 |
20030080059 | Peterson | May 2003 | A1 |
20030097086 | Gura | May 2003 | A1 |
20030105435 | Taylor | Jun 2003 | A1 |
20030113931 | Pan | Jun 2003 | A1 |
20030114787 | Gura | Jun 2003 | A1 |
20030138348 | Bell et al. | Jul 2003 | A1 |
20030187479 | Thong | Oct 2003 | A1 |
20040019312 | Childers | Jan 2004 | A1 |
20040019320 | Childers | Jan 2004 | A1 |
20040030277 | O'Mahony et al. | Feb 2004 | A1 |
20040037986 | Houston et al. | Feb 2004 | A1 |
20040054315 | Levin et al. | Mar 2004 | A1 |
20040082903 | Micheli | Apr 2004 | A1 |
20040084358 | O'Mahony et al. | May 2004 | A1 |
20040099593 | DePaolis | May 2004 | A1 |
20040147900 | Polaschegg | Jul 2004 | A1 |
20040168963 | King | Sep 2004 | A1 |
20040215090 | Erkkila | Oct 2004 | A1 |
20040257409 | Cheok | Dec 2004 | A1 |
20050006296 | Sullivan | Jan 2005 | A1 |
20050056592 | Braunger | Mar 2005 | A1 |
20050065760 | Murtfeldt | Mar 2005 | A1 |
20050101901 | Gura | May 2005 | A1 |
20050113796 | Taylor | May 2005 | A1 |
20050126961 | Bissler | Jun 2005 | A1 |
20050131332 | Kelly | Jun 2005 | A1 |
20050126998 | Childers | Jul 2005 | A1 |
20050148923 | Sternby | Jul 2005 | A1 |
20050150832 | Tsukamoto | Jul 2005 | A1 |
20050230313 | O'Mahony et al. | Oct 2005 | A1 |
20050234354 | Rowlandson | Oct 2005 | A1 |
20050234381 | Niemetz | Oct 2005 | A1 |
20050274658 | Rosenbaum | Dec 2005 | A1 |
20060025661 | Sweeney | Feb 2006 | A1 |
20060037483 | Kief | Feb 2006 | A1 |
20060217771 | Soykan | Feb 2006 | A1 |
20060157413 | Bene | Jul 2006 | A1 |
20060189926 | Hall et al. | Aug 2006 | A1 |
20060195064 | Plahey | Aug 2006 | A1 |
20060226079 | Mori | Oct 2006 | A1 |
20060241543 | Gura | Oct 2006 | A1 |
20060241709 | Soykan | Oct 2006 | A1 |
20060264894 | Moberg | Nov 2006 | A1 |
20070007208 | Brugger et al. | Jan 2007 | A1 |
20070055296 | Stergiopulos | Mar 2007 | A1 |
20070066928 | Lannoy | Mar 2007 | A1 |
20070138011 | Hofmann | Jun 2007 | A1 |
20070175827 | Wariar | Aug 2007 | A1 |
20070179431 | Roberts | Aug 2007 | A1 |
20070213665 | Curtin | Sep 2007 | A1 |
20070215545 | Bissler | Sep 2007 | A1 |
20070243113 | DiLeo | Oct 2007 | A1 |
20070255250 | Moberg | Nov 2007 | A1 |
20080006570 | Gura | Jan 2008 | A1 |
20080011664 | Karoor | Jan 2008 | A1 |
20080015493 | Childers et al. | Jan 2008 | A1 |
20080021337 | Li | Jan 2008 | A1 |
20080051696 | Curtin | Feb 2008 | A1 |
20080053905 | Brugger | Mar 2008 | A9 |
20080067132 | Ross | Mar 2008 | A1 |
20080215247 | Tonelli | Sep 2008 | A1 |
20080217245 | Rambod | Sep 2008 | A1 |
20080241031 | Li | Oct 2008 | A1 |
20080292935 | Roelofs | Nov 2008 | A1 |
20090012864 | Goldberg | Jan 2009 | A1 |
20090020471 | Tsukamoto | Jan 2009 | A1 |
20090078636 | Uchi | Mar 2009 | A1 |
20090084199 | Wright | Apr 2009 | A1 |
20090101552 | Fulkerson | Apr 2009 | A1 |
20090101577 | Fulkerson | Apr 2009 | A1 |
20090120864 | Fulkerson | May 2009 | A1 |
20090127193 | Updyke | May 2009 | A1 |
20090149795 | O'Mahony et al. | Jun 2009 | A1 |
20090216045 | Singh | Aug 2009 | A1 |
20090266358 | Sacristan Rock | Oct 2009 | A1 |
20090275849 | Stewart | Nov 2009 | A1 |
20090275883 | Chapman | Nov 2009 | A1 |
20090281484 | Childers | Nov 2009 | A1 |
20090282980 | Gura | Nov 2009 | A1 |
20100004588 | Yeh | Jan 2010 | A1 |
20100007838 | Fujimoto | Jan 2010 | A1 |
20100010429 | Childers | Jan 2010 | A1 |
20100018923 | Rohde et al. | Jan 2010 | A1 |
20100030151 | Kirsch | Feb 2010 | A1 |
20100051529 | Grant et al. | Mar 2010 | A1 |
20100051552 | Rohde | Mar 2010 | A1 |
20100076364 | O'Mahony et al. | Mar 2010 | A1 |
20100078381 | Merchant | Apr 2010 | A1 |
20100078387 | Wong | Apr 2010 | A1 |
20100084330 | Wong | Apr 2010 | A1 |
20100094158 | Solem | Apr 2010 | A1 |
20100100027 | Schilthuizen | Apr 2010 | A1 |
20100101195 | Clements | Apr 2010 | A1 |
20100102190 | Zhu et al. | Apr 2010 | A1 |
20100114001 | O'Mahony | May 2010 | A1 |
20100114012 | Sandford | May 2010 | A1 |
20100137693 | Porras | Jun 2010 | A1 |
20100168546 | Kamath | Jul 2010 | A1 |
20100168641 | O'Mahony et al. | Jul 2010 | A1 |
20100213127 | Castellarnau | Aug 2010 | A1 |
20100217181 | Roberts | Aug 2010 | A1 |
20100224492 | Ding | Sep 2010 | A1 |
20100234795 | Wallenas | Sep 2010 | A1 |
20100241045 | Kelly | Sep 2010 | A1 |
20100252490 | Fulkerson | Oct 2010 | A1 |
20100312172 | Hoffman | Dec 2010 | A1 |
20100312174 | Hoffman | Dec 2010 | A1 |
20100314314 | Ding | Dec 2010 | A1 |
20100326911 | Rosenbaum | Dec 2010 | A1 |
20110009798 | Kelly | Jan 2011 | A1 |
20110017665 | Updyke | Jan 2011 | A1 |
20110048949 | Ding et al. | Mar 2011 | A1 |
20110066043 | Banet | Mar 2011 | A1 |
20110077574 | Sigg | Mar 2011 | A1 |
20110079558 | Raimann | Apr 2011 | A1 |
20110087187 | Beck | Apr 2011 | A1 |
20110130666 | Dong | Jun 2011 | A1 |
20110163034 | Castellarnau | Jul 2011 | A1 |
20110171713 | Bluchel | Jul 2011 | A1 |
20110184340 | Tan | Jul 2011 | A1 |
20110220562 | Beiriger | Sep 2011 | A1 |
20110247973 | Sargand | Oct 2011 | A1 |
20110272337 | Palmer | Nov 2011 | A1 |
20110272352 | Braig | Nov 2011 | A1 |
20110297593 | Kelly | Dec 2011 | A1 |
20110315611 | Fulkerson | Dec 2011 | A1 |
20110315632 | Freije | Dec 2011 | A1 |
20120016228 | Kroh | Jan 2012 | A1 |
20120018377 | Tsukamoto | Jan 2012 | A1 |
20120083729 | Childers | Apr 2012 | A1 |
20120085707 | Beiriger | Apr 2012 | A1 |
20120092025 | Volker | Apr 2012 | A1 |
20120095402 | Lande | Apr 2012 | A1 |
20120115248 | Ansyln | May 2012 | A1 |
20120220528 | VanAntwerp | Aug 2012 | A1 |
20120248017 | Beiriger | Oct 2012 | A1 |
20120258545 | Ash | Oct 2012 | A1 |
20120258546 | Marran | Oct 2012 | A1 |
20120273354 | Orhan et al. | Nov 2012 | A1 |
20120273415 | Gerber | Nov 2012 | A1 |
20120273420 | Gerber | Nov 2012 | A1 |
20120277546 | Soykan | Nov 2012 | A1 |
20120277551 | Gerber | Nov 2012 | A1 |
20120277552 | Gerber | Nov 2012 | A1 |
20120277604 | Gerber | Nov 2012 | A1 |
20120277650 | Gerber | Nov 2012 | A1 |
20120277655 | Gerber | Nov 2012 | A1 |
20120277722 | Gerber | Nov 2012 | A1 |
20120303079 | Mahajan | Nov 2012 | A1 |
20130006128 | Olde et al. | Jan 2013 | A1 |
20130018095 | Vath | Jan 2013 | A1 |
20130019179 | Zhao | Jan 2013 | A1 |
20130020237 | Wilt et al. | Jan 2013 | A1 |
20130023812 | Hasegawa et al. | Jan 2013 | A1 |
20130025357 | Noack et al. | Jan 2013 | A1 |
20130027214 | Eng | Jan 2013 | A1 |
20130028809 | Barton | Jan 2013 | A1 |
20130030347 | Sugioka | Jan 2013 | A1 |
20130030348 | Lauer | Jan 2013 | A1 |
20130030356 | Ding | Jan 2013 | A1 |
20130037142 | Farrell | Feb 2013 | A1 |
20130037465 | Heyes | Feb 2013 | A1 |
20130056418 | Kopperschmidt et al. | Mar 2013 | A1 |
20130072895 | Kreischer et al. | Mar 2013 | A1 |
20130075314 | Nikolic | Mar 2013 | A1 |
20130087210 | Brandl et al. | Apr 2013 | A1 |
20130110028 | Bachmann et al. | May 2013 | A1 |
20130116578 | An | May 2013 | A1 |
20130199998 | Kelly | Aug 2013 | A1 |
20130213890 | Kelly | Aug 2013 | A1 |
20130213891 | Karoor | Aug 2013 | A1 |
20130228516 | Jonsson | Sep 2013 | A1 |
20130274642 | Soykan | Oct 2013 | A1 |
20130324915 | (Krensky)Britton | Dec 2013 | A1 |
20130330208 | Ly | Dec 2013 | A1 |
20130331774 | Farrell | Dec 2013 | A1 |
20140001112 | Karoor | Jan 2014 | A1 |
20140018728 | Plahey | Jan 2014 | A1 |
20140042092 | Akonur | Feb 2014 | A1 |
20140065950 | Mendelsohn | Mar 2014 | A1 |
20140088442 | Soykan | Mar 2014 | A1 |
20140110340 | White | Apr 2014 | A1 |
20140110341 | White | Apr 2014 | A1 |
20140138294 | Fulkerson | May 2014 | A1 |
20140158538 | Collier | Jun 2014 | A1 |
20140158588 | Pudil | Jun 2014 | A1 |
20140158623 | Pudil | Jun 2014 | A1 |
20140190876 | Meyer | Jul 2014 | A1 |
20140190885 | Meyer | Jul 2014 | A1 |
20140190886 | Pudil | Jul 2014 | A1 |
20140190891 | Lura | Jul 2014 | A1 |
20140217028 | Pudil | Aug 2014 | A1 |
20140217030 | Meyer | Aug 2014 | A1 |
20140220699 | Pudil | Aug 2014 | A1 |
20140251908 | Ding | Sep 2014 | A1 |
20140262812 | Longhenry | Sep 2014 | A1 |
20140326671 | Kelly | Nov 2014 | A1 |
20140336568 | Wong | Nov 2014 | A1 |
20150057602 | Mason | Feb 2015 | A1 |
20150108069 | Merchant | Apr 2015 | A1 |
20150108609 | Kushida | Apr 2015 | A1 |
20150114891 | Meyer | Apr 2015 | A1 |
20150144539 | Pudil | May 2015 | A1 |
20150144542 | Pudil | May 2015 | A1 |
20150157960 | Pudil | Jun 2015 | A1 |
20150238673 | Gerber | Aug 2015 | A1 |
20150250937 | Pudil | Sep 2015 | A1 |
20150251161 | Pudil | Sep 2015 | A1 |
20150251162 | Pudil | Sep 2015 | A1 |
20150258266 | Merchant | Sep 2015 | A1 |
20150306292 | Pudil | Oct 2015 | A1 |
20150367051 | Gerber | Dec 2015 | A1 |
20150367052 | Gerber | Dec 2015 | A1 |
20150367055 | Pudil | Dec 2015 | A1 |
20150367056 | Gerber | Dec 2015 | A1 |
20150367057 | Gerber | Dec 2015 | A1 |
20150367058 | Gerber | Dec 2015 | A1 |
20150367059 | Gerber | Dec 2015 | A1 |
20150367060 | Gerber | Dec 2015 | A1 |
20160236188 | Menon | Aug 2016 | A1 |
20160243299 | Gerber | Aug 2016 | A1 |
20160243540 | Menon | Aug 2016 | A1 |
20160243541 | Menon | Aug 2016 | A1 |
20170087533 | Hobot | Mar 2017 | A1 |
20180221852 | Pudil | Aug 2018 | A1 |
Number | Date | Country |
---|---|---|
1487853 | Apr 2004 | CN |
102573618 | Jul 2012 | CN |
102762268 | Oct 2012 | CN |
103402563 | Nov 2013 | CN |
103747818 | Apr 2014 | CN |
103889478 | Jun 2014 | CN |
104936633 | Sep 2015 | CN |
105992599 | May 2016 | CN |
105658326 | Jun 2016 | CN |
106413878 | Feb 2017 | CN |
3110128 | Sep 1982 | DE |
102011052188 | Jan 2013 | DE |
0266795 | Nov 1987 | EP |
0264695 | Apr 1988 | EP |
0614081 | Jul 2000 | EP |
1085295 | Nov 2001 | EP |
711182 | Jun 2003 | EP |
1364666 | Nov 2003 | EP |
0906768 | Feb 2004 | EP |
1450879 | Oct 2008 | EP |
1991289 | Nov 2008 | EP |
1592494 | Jun 2009 | EP |
2100553 | Sep 2009 | EP |
2575827 | Dec 2010 | EP |
2576453 | Dec 2011 | EP |
2446908 | May 2012 | EP |
2701580 | Nov 2012 | EP |
2701595 | Nov 2012 | EP |
1545652 | Jan 2013 | EP |
1684625 | Jan 2013 | EP |
2142234 | Jan 2013 | EP |
2550984 | Jan 2013 | EP |
1345856 | Mar 2013 | EP |
1938849 | Mar 2013 | EP |
2219703 | Mar 2013 | EP |
2564884 | Mar 2013 | EP |
2564885 | Mar 2013 | EP |
2344220 | Apr 2013 | EP |
1345687 | Jun 2013 | EP |
2701596 | Mar 2014 | EP |
2950836 | Dec 2015 | EP |
3546042 | Oct 2019 | EP |
3626280 | Mar 2020 | EP |
S5070281 | Jun 1975 | JP |
S51-55193 | May 1976 | JP |
S51-131393 | Nov 1976 | JP |
S61164562 | Jul 1986 | JP |
2981573 | Nov 1999 | JP |
2005511250 | Apr 2005 | JP |
H4-90963 | May 2005 | JP |
2007-44602 | Feb 2007 | JP |
200744602 | Feb 2007 | JP |
200744602 | Feb 2007 | JP |
5-99464 | Oct 2012 | JP |
2013502987 | Oct 2013 | JP |
1701752 | Sep 2006 | WF |
9106326 | May 1991 | WO |
9532010 | Nov 1995 | WO |
9937342 | Jul 1999 | WO |
2000038591 | Jul 2000 | WO |
0057935 | Oct 2000 | WO |
200066197 | Nov 2000 | WO |
200170307 | Sep 2001 | WO |
2001085295 | Sep 2001 | WO |
0185295 | Nov 2001 | WO |
2002043859 | Jun 2002 | WO |
200303677 | May 2003 | WO |
2003043680 | May 2003 | WO |
WO 2003041764 | May 2003 | WO |
2003051422 | Jun 2003 | WO |
2004008826 | Jan 2004 | WO |
2004009156 | Jan 2004 | WO |
2004030716 | Apr 2004 | WO |
2004030717 | Apr 2004 | WO |
2004064616 | Aug 2004 | WO |
2004062710 | Oct 2004 | WO |
WO 2005062973 | Jul 2005 | WO |
2005123230 | Dec 2005 | WO |
2007089855 | Aug 2007 | WO |
WO 20070103411 | Sep 2007 | WO |
2008075951 | Jun 2008 | WO |
2009026603 | Dec 2008 | WO |
2009064984 | May 2009 | WO |
2009157877 | Dec 2009 | WO |
2009157878 | Dec 2009 | WO |
20090157877 | Dec 2009 | WO |
2010028860 | Mar 2010 | WO |
2010102190 | Nov 2010 | WO |
2010141949 | Dec 2010 | WO |
WO 2011017215 | Feb 2011 | WO |
2011025705 | Mar 2011 | WO |
2012148781 | Nov 2012 | WO |
2012148786 | Nov 2012 | WO |
2012148789 | Nov 2012 | WO |
2012162515 | Nov 2012 | WO |
2012172398 | Dec 2012 | WO |
2013019179 | Feb 2013 | WO |
2013019994 | Feb 2013 | WO |
2013022024 | Feb 2013 | WO |
2013022837 | Feb 2013 | WO |
2013025844 | Feb 2013 | WO |
2013025957 | Feb 2013 | WO |
2013027214 | Feb 2013 | WO |
2013028809 | Feb 2013 | WO |
WO 2013019179 | Feb 2013 | WO |
WO 2013019994 | Feb 2013 | WO |
WO 2013-025957 | Feb 2013 | WO |
WO 2013028809 | Feb 2013 | WO |
WO 2013019179 | Feb 2013 | WO |
WO2014121238 | Feb 2013 | WO |
2013030642 | Mar 2013 | WO |
2013030643 | Mar 2013 | WO |
2012060700 | May 2013 | WO |
2013101888 | Jul 2013 | WO |
2013103607 | Jul 2013 | WO |
2013103906 | Jul 2013 | WO |
WO 2013103607 | Jul 2013 | WO |
WO 2013109922 | Jul 2013 | WO |
2013114063 | Aug 2013 | WO |
2013121162 | Aug 2013 | WO |
14066254 | May 2014 | WO |
14066255 | May 2014 | WO |
14077082 | May 2014 | WO |
2014121162 | Aug 2014 | WO |
2014121163 | Aug 2014 | WO |
2014121167 | Aug 2014 | WO |
2014121169 | Aug 2014 | WO |
2015060914 | Apr 2015 | WO |
WO 2015080895 | Apr 2015 | WO |
WO 2015060914 | Apr 2015 | WO |
WO 2015126879 | Aug 2015 | WO |
2015142624 | Sep 2015 | WO |
2015199764 | Dec 2015 | WO |
2015199765 | Dec 2015 | WO |
2015199863 | Dec 2015 | WO |
2015199864 | Dec 2015 | WO |
WO 2015-199863 | Dec 2015 | WO |
WO 2015-199864 | Dec 2015 | WO |
WO 2015199765 | Dec 2015 | WO |
WO 2016191039 | Dec 2016 | WO |
WO 2016191041 | Dec 2016 | WO |
WO 2013-028809 | Feb 2018 | WO |
Entry |
---|
Brynda, et al., The detection of toman 2-microglcbuiin by grating coupler immunosensor with three dimensional antibody networks. Biosensors & Bioelectronics, 1999, 363-368, 14(4). |
Wheaton, et al., Dowex Ion Exchange Resins-Fundamentals of Ion Exchange; Jun. 2000, pp. 1-9. http://www.dow.com/scripts/litorder.asp?filepath=liquidseps/pdfs/noreg/177-01837.pdf. |
Zhong, et al., Miniature urea sensor based on H(+)-ion sensitive field effect transistor and its application in clinical analysis, Chin. J. Biotechnol., 1992, 57-65. 8(1). |
PCT/US2012/034331, International Search Report and Written Opinion dated Jul. 9, 2012. |
Roberts M, The regenerative dialysis (REDY) sorbent system. Nephrology, 1998, 275-278:4. |
U.S. Appl. No. 61/480,544, dated Apr. 29, 2011. |
U.S. Appl. No. 61/480,541 dated Apr. 29, 2011. |
Hemametrics, Crit-Line Hematocrit Accuracy, 2003, 1-5, vol. 1, Tech Note No. 11 (Rev. D). |
Weissman, S., et al., Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Clin. Infec. Dis, (Jul. 29, 1999): 223-224. |
PCT/US2012/034334, International Search Report, dated Jul. 6, 2012. |
PCT/US2012/034335, International Search Report, dated Sep. 5, 2012. |
PCT/US/2012/034327, International Search Report, dated Aug. 13, 2013. |
PCT/US/2012/034329, International Search Report, dated Dec. 3, 2012. |
International Search Report from PCT/US2012/051946 dated Mar. 4, 2013. |
U.S. Appl. No. 61/526,209. |
Wang, Fundamentals of intrathoracic impedance monitoring in heart failure, Am. J. Cardiology, 2007, 3G-10G: Suppl. |
PCT/US2014/067650 International Search Report Written Opinion dated Mar. 9, 2015. |
Bleyer, et al., Sudden and cardiac death rated in hemodialysis patients, Kidney International. 1999, 1553-1559: 55. |
PCT/US2012/034333, International Preliminary Report on Patentability, dated Oct. 29, 2013. |
PCT/US2012/034333, International Search Report, dated Aug. 29, 2012. |
PCT/US2012/034330, International Preliminary Report on Patentability, dated Oct. 29, 2013. |
PCT/US2014/065950 International Search Report and Written Opinion dated Feb. 24, 2015. |
Culleton, BF et al. Effect of Frequent Nocturnal Hemodialysis vs. Conventional Hemodialysis on Left Ventricular Mass and Quality of Life. 2007 Journal of the American Medical Association 298 (11), 1291-1299. |
U.S. Appl. No. 13/757,722, filed Feb. 1, 2013. |
U.S. Appl. No. 13/757,794, filed Feb. 2, 2012. |
U.S. Appl. No. 13/791,755, filed Mar. 8, 2013. |
U.S. Appl. No. 13/424,479 dated Nov. 1, 2012. |
U.S. Appl. No. 13/757,792, filed Feb. 2, 2013. |
U.S. Appl. No. 13/757,794, filed Feb. 2, 2013. |
U.S. Appl. No. 13/837,287, filed Mar. 15, 2013. |
U.S. Appl. No. 13/424,429 dated Nov. 1, 2012. |
Redfield, et al., Restoration of renal response to atrial natriuretic factor in experimental low-output heat failure, Am. J. Physiol., Oct. 1, 1989, R917-923:257. |
Rogoza, et al., Validation of A&D UA-767 device for the self-measurement of blood pressure, Blood Pressure Monitoring, 2000, 227-231, 5(4). |
Lima, et al., An electrochemical sensor based on nanostructure hollandite-type manganese oxide for detection of potassium ion, Sensors, Aug. 24, 2009, 6613-8625, 9. |
MacLean, et, al., Effects of hindlimb contraction on pressor and muscle interstitial metabolite responses in the cat, J. App. Physiol., 1998, 1583-1592, 85(4). |
U.S. Appl. No. 13/757,693, dated Feb. 1, 2013. |
PCT Application, PCT/US2013/020404, filed Jan. 4, 2013. |
U.S. Appl. No. 13/424,525, filed Nov. 1, 2012. |
U.S. Appl. No. 13/836,973, filed Mar. 15, 2013. |
U.S. Appl. No. 14/259,655, filed Apr. 23, 2014. |
U.S. Appl. No. 14/259,589, filed Apr. 23, 2014. |
U.S. Appl. No. 13/757,693, filed Jan. 4, 2013. |
U.S. Appl. No. 13/836,079, filed Mar. 15, 2013. |
U.S. Appl. No. 14/240,129, filed Aug. 22, 2013. |
PCT/US2014/014346 International Search Report and Written Opinion. |
U.S. Appl. No. 13/100,847, filed Nov. 10, 2011, C-Tech BioMedical Inc. |
U.S. Appl. No. 13/565,733, filed Aug. 2, 2012, Medtronic. |
U.S. Appl. No. 13/757,693, filed Feb. 1, 2013, Medtronic. |
U.S. Appl. No. 13/757,709, Feb. 1, 2013, Medtronic. |
U.S. Appl. No. 13/757,728, filed Feb. 1, 2013, Medtronic. |
U.S. Appl. No. 13/836,538, filed Mar. 15, 2013, Medtronic. |
U.S. Appl. No. 14/637,606_OA. |
U.S. Appl. No. 14/645,394_OA. |
U.S. Appl. No. 13/835,735, filed Mar. 15, 2013. |
PCT/US2014/014345 International Search Report and Written Opinion, dated May 2014. |
U.S. Appl. No. 13/835,735 IDS, filed Jun. 13, 2013. |
PCT/US2014/014357 International Search Report and Written Opinion dated May 19, 2014. |
Ronco et al. 2008, Cardiorenal Syndrome, Journal American College Cardiology, 52:1527-1539, Abstract. |
Overgaard, et al., Activity-induced recovery of excitability in K+-depressed rat soleus muscle, Am. J. P 280: R48-R55, Jan. 1, 2001. |
Overgaard et al., Relations between excitability and contractility in rate soleusmuscle: role of the NA+-K+ pump and NA+-K-S gradients. Journal of Physiology, 1999, 215-225, 518(1). |
PCT/US2015/032492 International Search Report dated Nov. 19, 2015. |
Coast, et al. 1990, An approach to Cardiac Arrhythmia analysis Using Hidden Markov Models, IEEE Transactions on Biomedical Engineering. 1990, 37(9):826-835. |
U.S. Appl. No. 61/480,532, filed Apr. 29, 2011. |
U.S. Appl. No. 61/480,530, filed Apr. 29, 2011. |
U.S. Appl. No. 61/480,528 dated Apr. 29, 2011. |
Secemsky, et al., High prevalence of cardiac autonomic dysfunction and T-wave alternans in dialysis patients. Heart Rhythm, Apr. 2011, 592-598 : vol. 8, No. 4. |
Wei, et al., Fullerene-cryptand coated piezoelectric crystal urea sensor based on urease, Analytica Chimica Acta, 2001,77-85:437. |
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 1-140. |
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 141-280. |
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 281-420. |
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 421-534. |
U.S. Appl. No. 13/368,225 dated Feb. 7, 2012. |
Leifer et al., A Study on the Temperature Variation of Rise Velocity for Large Clean Bubbles, J. Atmospheric & Oceanic Tech., vol. 17, pp. 1392-1402, Oct. 2000. |
Talaia, Terminal Velocity of a Bubble Rise in a Liquid Column, World Acad. of Sci., Engineering & Tech., vol. 28, pp. 264-268, Published Jan. 1, 2007. |
The FHN Trial Group. In-Center. Hemodialysis Six Times per Week versus Three Times per Week, New England Journal of Medicine, 2010 Abstract. |
Gotch FA, Sargent JA A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney int. 1985: 28:526-34. |
Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V and analysis of error. J Am Soc Nephrol, 1993: 4:1205-13. |
Steil et al. Intl Journ Artif Organs, 1993, In Vivo Verification of an Automatic Noninvasive System for Real Time Kt Evaluation, ASAIO J., 1993, 39:M348-52. |
PCT/US2012/034332, International Search Report, dated Jul. 5, 2012. |
PCT/US2015/019901 International Search Report and Written Opinion dated Jun. 5, 2015. |
Siegenthaler, et al., Pulmonary fluid status monitoring with intrathoracic impedance, Journal of Clinical Monitoring and Computing, 24:449-451, published Jan. 12, 2011. |
U.S. Appl. No. 61/480,544. unpublished. |
John Wm Agar: Review: Understanding sorbent dialysis systems, Nephrology, vol. 15, No. 4, Jun. 1, 2010, pp. 406-411. |
EP. App. 14746193.3 Search Report dated Oct. 19, 2016. |
PCT/US2015/016270 International Search Report and Written Opinion dated Jun. 5, 2015. |
Office Action in U.S. Appl. No. 14/269,589, dated Nov. 4, 2016. |
Office Action in U.S. Appl. No. 13/586,824 dated Dec. 21, 2015. |
Office Action in U.S. Appl. No. 13/586,824 dated Jun. 4, 2015. |
Eureopean Search Report for App. No. EP14745643 dated Oct. 6, 2016. |
PCT/US15/18587 International Preliminary Report on Patentability dated Jun. 6, 2016. |
European Search Opinion for App. No. EP12826180 dated Mar. 19, 2015. |
European Search Opinion for App. No. EP12826180 dated Jan. 18, 2016. |
Khanna, Ramesh, R.T. Krediet, and Karl D. Nolph. Nolph and Gokals Textbook of Peritoneal Dialysis New York: Springer 2009. Print. |
Ruperez et al., Comparison of a tubular pulsatile pump and a volumetric pump for continuous venovenous renal replacement therapy in a pediatric animal model, 51 ASAIO J. 372, 372-375 (2005). |
St. Peter et al., Liver and kidney preservation by perfusion, 359 The Lancet 604, 606(2002). |
Dasselaar et al., Measurement of relative blood volume changes during hemodialysis: merits and limitations, 20 Nephrol Dial Transpl. 2043, 2043-2044 (2005). |
Ralph T. Yang, Adsorbents: Fundamentals and Applications 109 (2003). |
Henny H. Billett, Hemoglobin and Hematocrit, in Clinical Methods: The History, Physical, and Laboratory Examinations 719(HK Walker, WD Hall, & JW Hurst ed., 1990). |
Office Action in U.S. Appl. No. 13/565,733 dated Jan. 11, 2016. |
Office Action in U.S. Appl. No. 13/565,733 dated Jun. 11, 2015. |
U.S. Appl. No. 13/424,454, dated Nov. 1, 2012. |
Office Action in U.S. Appl. No. 13/757,792 dated Jun. 2, 2016. |
Office Action in U.S. Appl. No. 13/757,796 dated Apr. 13, 2015. |
Office Action in U.S. Appl. No. 13/757,796 dated Dec. 21, 2015. |
Office Action in U.S. Appl. No. 13/835,735 dated Oct. 13, 2015. |
Office Action in U.S. Appl. No. 13/836,079 dated Jun. 30, 2016. |
Office Action in U.S. Appl. No. 13/791,755 dated Mar. 16, 2016. |
Office Action in U.S. Appl. No. 13/791,755 dated Aug. 9, 2016. |
Office Action in U.S. Appl. No. 13/835,735 dated Jun. 16, 2016. |
Office Action in U.S. Appl. No. 13/836,079 dated Nov. 6, 2015. |
U.S. Appl. No. 13/424,467, filed Nov. 1, 2012. |
Office Action in App. No. AU 2015280604 dated Apr. 8, 2016. |
International Search Report from International Application No. PCT/US2014/014347 dated May 9, 2014. |
PCT/US2016/030319 Written Opinion dated Jul. 27, 2016. |
PCT/US2016/030320 Written Opinion dated Jul. 27, 2016. |
PCT/US2012/014347, International Search Report. |
PCT/US2015/016273 International Search Report and Written Opinion dated Jun. 9, 2015. |
Wester et al., A regenerable postassium and phosphate sorbent system to enhance dialysis efficacy and device portability: an in vitro study Nephrol Dial Transplant (2013) 28: 2364-2371 Jul. 3, 2013. |
Office Action in App. No. JP 2016-515476 dated Dec. 26, 2016. |
Japanese Patent Publication No. S50-70281A. |
PCT/US2015/032494 Written Opinion dated Nov. 19, 2015. |
PCT/US2015/032494 International Search Report dated Nov. 19, 2015. |
PCT/US2015/019901 International Preliminary Report on Patentability dated May 27, 2016. |
PCT/US2015/019901 Written Opinion dated May 27, 2016. |
PCT/US2015/019901 Written Opinion dated Jun. 5, 2015. |
PCT/US2015/019901 International Search Report dated Jun. 5, 2015. |
PCT/US2015/032485 International Preliminary Report on Patentability dated May 11, 2016. |
PCT/US20115/032485 International Preliminary Report on Patentability dated May 11, 2016. |
PCT/US2016/030304 International Search Report dated Jul. 27, 2016. |
PCT/US2016/030304 Written Opinion dated Jul. 27, 2016. |
PCT/US2016/030312 Written Opinion dated Jul. 28, 2016. |
PCT/US2016/030312 International Search Report dated Jul. 28, 2016. |
PCT/US2016/030319 International Search Report dated Jul. 27, 2016. |
PCT/US2016/030320 Written Opinion dated Jul. 28, 2016. |
PCT/US2016/030320 International Search Report dated Jul. 28, 2016. |
PCT/US2015/032485 Written Opinion dated Oct. 16, 2015. |
PCT/US2015/032485 Written Opinion dated Oct. 16, 2016. |
PCT/US2015/032485 International Search Report and Written Opinion dated Oct. 16, 2015. |
U.S. Appl. No. 13/424,533, dated Nov. 1, 2012. |
PCT/US2016/030320 International Preliminary Report on Patentability, dated Apr. 20, 2017. |
International Preliminary Report from International Application No. PCT/US2014/014348 dated Jan. 9, 2015. |
European Search Report from European Application No. EP 14746193.3 dated Oct. 19, 2016. |
European Search Report from European Application No. EP 14746193.3 dated Jun. 8, 2016. |
PCT/US2014/014345 Written Opinion dated Jun. 24, 2015. |
PCT/US2014/014345 International Search Report and Written Opinion dated May 30, 2014. |
Office Action in European Application No. 14746428.03 dated Feb. 8, 2017. |
European Search Report in European Application No. 14746428.03 dated Aug. 25, 2016. |
PCT/US2014/014346 Writtent Opinion dated Apr. 10, 2015. |
PCT/US2014/014346 International Search Report and Writtent Opinion dated May 23, 2014. |
EP 14746415.0 European Search Report dated Aug. 22, 2016. |
Office Action in European Application No. EP 14746415.0 dated Apr. 19, 2017. |
Office Action in European Application No. 14746415.0 dated Apr. 19, 2017. |
U.S. Appl. No. 13/424,490, filed Nov. 1, 2012. |
PCT/US2015/020047 International Search Report and Written Opinion dated Jun. 29, 2015. |
PCT/US2015/020047 International Preliminary Report on Patentability dated Jun. 30, 2015. |
PCT/US2015/020044 Written Opinion dated Jun. 21, 2016. |
PCT/US2015/020044 International Preliminary Report on Patentability dated Nov. 4, 2016. |
PCT/US2015/020044 International Search Report dated Jun. 30, 2015. |
US2015/019881 Written Opinion dated Jun. 16, 2016. |
US2015/019881 Written Opinion dated May 9, 2016. |
U.S. Appl. No. 13/424,517, dated Nov. 1, 2012. |
US2015/019881 International Search Report and Written Opinion dated Jun. 29, 2015. |
PCT/US2014/065950 International Preliminary Report on Patentability dated Oct. 28, 2015. |
PCT/US2015/032485 Written Opinion dated May 9, 2016. |
PCT/US2015/032492 Written Opinion dated Nov. 19, 2015. |
PCT/US2015/032494 International Preliminary Report on Patentablity dated Dec. 27, 2016. |
Office Action for Chinese Application No. 201580009562.5 dated Jul. 3, 2017. |
International Preliminary Report on Patentability for Application No. PCT/US2015/032492 dated Jun. 30, 2017. |
Office Action in European Application No. 14746193.3 dated Apr. 19, 2017. |
International Preliminary Report on Patentability for Application No. PCT/US2015/016273 dated Feb. 19, 2016. |
European Search Report for App. No. 15751391.2 dated Aug. 4, 2017. |
European Search Report and supplementary Search Report for App. No.14865374.4 dated Jun. 12, 2017. |
European Search Report and Supplemental Search Report in European Application No. 14865374.4 dated Jun. 12, 2017. |
PCT/US2015/020046 International Search Report and Written Opinion dated Jun. 29, 2015. |
U.S. Appl. No. 61/480,539 dated Apr. 29, 2011. |
U.S. Appl. No. 61/480,535 dated Apr. 29, 2011. |
PCT/US2015/020044 International Search Report Written Opinion dated Jun. 30, 2015. |
Nedelkov, et. al., Design of buffer exchange surfaces and sensor chips for biosensor chip mass spectrometry, Proteomics, 2002, 441-446, 2(4). |
European Search Report App 14865374.4, dated Jun. 12, 2017. |
Chinese Office Action for App. No. 201711179516.7, dated Feb. 19, 2020. |
Chinese Office Action for App. No. 201711179528.X, dated Jul. 27, 2020. |
Chinese Office Action for App. No. 201711179528.X, dated Mar. 26, 2020. |
Chinese Office Action for App. No. 201810580243.5, dated Jul. 3, 2020. |
Chinese Office Action in App. No. 201580009563.X, dated Mar. 13, 2018. |
European Search Report for App. No. 15812081.6, dated Mar. 8, 2018. |
European Search Report for App. No. 18153940.4, dated Jun. 12, 2018. |
European Search Report for App. No. 18153940.4, dated Sep. 28, 2018. |
European Search Report for App. No. 19191469.6, dated Jan. 8, 2020. |
European Search Report for App. No. 19197167.0, dated Jan. 30, 2020. |
European Search Report for App. No. 20158130.3, dated Jul. 8, 2020. |
European Search Report for App. No. 20164524.9, dated Aug. 21, 2020. |
European Search Report for EP 15811439, dated Feb. 15, 2018. |
European Search Report for EP App. No. 15810804.3, dated Feb. 15, 2018. |
European Search Report for EP App. No. 15811326.6, dated Feb. 14, 2018. |
European Search Report for EP App. No. 15811573.3, dated Feb. 15, 2018. |
European Search Report for EP App. No. 15812413.1, dated Feb. 2, 2018. |
European Search Report for EP18177673.3-1104 (dated Oct. 19, 2018). |
European Search Report for EP18177683.2-1104 (dated Nov. 8, 2018). |
European Search Report in EP 15811454, dated Feb. 15, 2018. |
European Search Report in EP 15812559.1, dated Jan. 31, 2018. |
Office Action for Chinese App. No. 201711179516.7, dated Sep. 11, 2019. |
Office Action for Chinese App. No. 201810042927, dated Sep. 23, 2019. |
Office Action for European App. No. 17203968.7, dated Nov. 14, 2019. |
Office Action in Japanese Application No. 2016-553344, dated Apr. 24, 2018. |
PCT/US2016/030304_IPRP. |
PCT/US2016/030319_IPRP. |
Search Report for Brazilian App. No. BR112016019111, dated Mar. 12, 2020. |
Search Report for EP App. No. 17203984.4, dated Mar. 29, 2018. |
Search Report for European App. No. 19187736.4, dated Dec. 16, 2019. |
Search Report in EP App. No. 15752771, dated Nov. 22, 2017. |
Number | Date | Country | |
---|---|---|---|
20210178365 A1 | Jun 2021 | US |
Number | Date | Country | |
---|---|---|---|
62519933 | Jun 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15958337 | Apr 2018 | US |
Child | 17185604 | US |